Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Phase 4 Recruiting 40 enrolled Northwestern University Regeneron Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

Timeline

Start: 2024-08-12
Primary completion: 2027-06
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dupilumab	Monoclonal antibody	—	Subcutaneous

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications